One Case of Liver Injury Induced by Bosentan Tablets

doi:10.19803/j.1672-8629.2019.12.10

Abstract

CLC Number:

R994.11

PAN Manmang, LIU Xiaoyan, ZUO Xiaocong, ZHOU Lingyun, GU Zhi chun. One Case of Liver Injury Induced by Bosentan Tablets[J]. Chinese Journal of Pharmacovigilance, 2019, 16(12): 757-758.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.2019.12.10

https://zgywjj.magtechjournal.com/EN/Y2019/V16/I12/757

[1] 2015 ESC/ERS Guidelines for the diagnosis and treat ment of pulmonary hypertension[M]. European Heart Journal Advance Access published August 29, 2015.
[2] 中华医学会心血管病学分会.中国肺高血压诊断和治疗指南2018[J].中华心血管病杂志. 2018, 46(12):933-964.
[3] Barst RJ.A review of pulmonary arterial hypertension:role of ambrisentan[J]. Vasc Health Risk Manag, 2007, 3(1):11-22.
[4] 顾智淳,刘晓琰,倪晓珺,等.波生坦与华法林致INR降低1例[J].中国药物警戒, 2014, 11(6):379-380.
[5] Rubin L J, Badesch D B, Barst R J, et al.Bosentan therapy for pulmonary arterial hypertension[J].N Engl J Med,2002, 346(12):896-903.
[6] McLaughlin V V, Sitbon O, Badesch D B, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension[J]. Eur Respir J, 2005, 25(2):244-249.
[7] Sitbon O, Badesch D B, Channick R N, et al.Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension:a 1-year follow-up study[J].Chest, 2003, 124(1):247-254.
[8] Nagai Y, Okada E, Mihara S, et al.Severe Liver dysfunction due to bosentan in patient with mixed connective tissue disease[J].Eur J Dermatol, 2008, 18(2):190-191.
[9] Eriksson C,Gustavsson A,Kronvall T,et al.Hepatotoxicity by bosentan in a patient with portopulmonary hypertension:a case report and review of the literature[J]. J Gastrointesin Liver Dis, 2011, 20(1):77-80.
[10] Humbert M,Segal E S,Kiely D G,et al.Results of European postmarketing surveillance of bosentan in pulmonary hyper-tension[J].Eur Respir, 2007, 30(2):338-344.
[11] Girgis R E, Mathai S C, Krishnan J A, et al.Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases[J].J Heart Lung Transplant, 2005, 24(10):1626-1631.
[12] 葛俊波,徐永健.《内科学》[M]. 8版.人民卫生出版社,2014.
[13] Galiè N, Olschewski H, Oudiz R J, et al.Ambrisentan for the treatment of pulmonary arterial hypertension: results of the Ambrisentan in Pulmonary Arterial Hypertension,Randomized, Double-Blind, Placebo-Controlled, Multicenter,Efficacy (ARIES) Study 1 and 2[J]. Circulation, 2008, 117(23):3010-3019.

[1]	LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850.
[2]	WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855.
[3]	XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862.
[4]	CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875.
[5]	CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882.
[6]	ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888.
[7]	SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895.
[8]	SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919.
[9]	YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923.
[10]	KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927.
[11]	LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
[12]	LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936.
[13]	ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940.
[14]	ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943.
[15]	CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946.

One Case of Liver Injury Induced by Bosentan Tablets

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics